These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 34733735)
1. Case report: identification of Ma J; Wang B; Meng E; Meng X Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735 [TBL] [Abstract][Full Text] [Related]
2. RET fusions in solid tumors. Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421 [TBL] [Abstract][Full Text] [Related]
3. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue. Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T Front Oncol; 2021; 11():704084. PubMed ID: 34497761 [TBL] [Abstract][Full Text] [Related]
4. Pralsetinib for the treatment of a Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397 [TBL] [Abstract][Full Text] [Related]
5. Decade in review: a new era for RET-rearranged lung cancers. Choudhury NJ; Drilon A Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819 [TBL] [Abstract][Full Text] [Related]
6. Predictive molecular pathology in metastatic thyroid cancer: the role of Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189 [TBL] [Abstract][Full Text] [Related]
7. RET Inhibitors in Non-Small-Cell Lung Cancer. Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226 [TBL] [Abstract][Full Text] [Related]
8. Precision therapy for RET-altered cancers with RET inhibitors. Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699 [TBL] [Abstract][Full Text] [Related]
9. RET kinase inhibitors for Vodopivec DM; Hu MI Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966 [TBL] [Abstract][Full Text] [Related]
11. Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer. Yokota T Case Rep Oncol; 2022; 15(3):833-840. PubMed ID: 36825106 [TBL] [Abstract][Full Text] [Related]
12. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC). Nguyen VQ; Geirnaert M J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992 [TBL] [Abstract][Full Text] [Related]
13. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC. De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A Front Oncol; 2024; 14():1307458. PubMed ID: 38420011 [TBL] [Abstract][Full Text] [Related]
14. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present). Acharya B; Frett B Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171 [TBL] [Abstract][Full Text] [Related]
15. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Roskoski R; Sadeghi-Nejad A Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153 [TBL] [Abstract][Full Text] [Related]
16. Precious Gene: The Application of RET-Altered Inhibitors. Gou Q; Gan X; Li L; Gou Q; Zhang T Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971 [TBL] [Abstract][Full Text] [Related]